Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 ...

Weight loss syringes of the brands "Wegovy", "Ozempic" and "Mounjaro" are sold at In der Achat Apotheke in Mitte, Germany. All doses of Novo Nordisk's highly popular weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the U.S. Food and Drug Administration's drug shortage database on Wednesday. It is a sign that Novo Nordisk's efforts to ramp up the supply of those weekly drugs are starting to pay off, as demand continues to skyrocket in the U.S. A ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.Danish pharmaceutical company Novo Nordisk (NVO -0.47%) is pioneering a new wave of medical treatment for diabetes and obesity care.The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic, Wegovy, Rybelsus, and Saxenda. The main compound that Ozempic, Wegovy, and Rybelsus share is called semaglutide.However, what sets Rybelsus apart from its sibling tre ...

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in patients with Type 2 diabetes compared with seven other diabetes medications. That includes insulin and older so-called GLP-1 drugs similar to Ozempic, the resea ...

Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross. Chart created using Benzinga ProFor those uninitiated, this bearish signal occurs when a stock's 50-day moving average drops below its 200-day moving average, hinting that more downside could be ahead. However, Novo Nordisk's future might not be as grim as this technical omen suggests. Let's dig into the numbers and explore whether there's a silver lining for investors in this pharma heavyweight.Bearish Signals Dominate, But Buying Pressure ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Novo Nordisk on Tuesday asked the Food and Drug Administration to prevent compounding pharmacies from making unapproved and often cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic, arguing that the medications are too complex for those manufacturers to make safely. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic an ...

Novo Nordisk (NVO) announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral semaglutide compared with placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE).The enrolled patient population comprised those with type 2 diabetes (T2D) and established cardiovascular disease and/or chronic kidney disease (CKD). Novo Nordisk further stated that 49% of the enrolled patients received SGLT2i, the standard-of-care ther ...

Novo Nordisk (NVO) shares have lost 4.5% in the past month compared with the industry's decline of 1.5%. The company has also underperformed in the sector and the S&P 500 in the past month, as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk's stock price primarily dipped after U.S. Senator Bernie Sanders criticized the company for charging hig ...

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors. Novo Nordisk's Alhemo is a monoclonal antibody that blocks the TFPI, a protein that prevents blood clotting. By inhibiting TFPI, Alhemo promotes thrombin productio ...